- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.01. | FDA lifts hold on an Intellia CRISPR drug trial | ||
| 27.01. | Roche, trailing in obesity, showcases new data for GLP-1 shot | ||
| 26.01. | China's edge in early-stage drugmaking 'likely to persist,' Pitchbook says | ||
| 26.01. | Sarepta, battling slowing sales, claims Duchenne gene therapy's impact grows with time | ||
| 26.01. | Biotech investor Cormorant secures $150M for another SPAC deal | ||
| 26.01. | Express Scripts considering settlement in FTC insulin price lawsuit | ||
| 26.01. | The formula for biotech success in 2026: Confidence, resilience and funding | ||
| 26.01. | The crucial role of raw material selection for success in cell therapy manufacturing | ||
| 26.01. | From detection to prevention: How sponsored testing can transform patient outcomes | ||
| 23.01. | Sanofi to seek approval of touted eczema drug despite mixed results | ||
| 23.01. | Novo climbs higher on 'strong' Wegovy pill launch; Terns tweaks leukemia drug deal | ||
| 23.01. | Congress eyes tackling healthcare consolidation | ||
| 22.01. | Investors load Corxel with $287M for a 'differentiated' obesity pill | ||
| 22.01. | Bristol Myers buys into Janux's 'masked' T cell engagers | ||
| 22.01. | FDA lays out new path to speed development of multiple myeloma drugs | ||
| 22.01. | BioMarin vets form Mendra to 'modernize' rare disease drug development | ||
| 21.01. | Corvus shares nearly triple on positive data for eczema pill | ||
| 21.01. | J&J eyes $100B in sales amid gains for cancer, immune drugs | ||
| 21.01. | Moderna cancer vaccine holds up; IO Biotech considers a sale | ||
| 20.01. | Valneva to withdraw Chikungunya vaccine from US amid safety woes | ||
| 20.01. | GSK to buy Rapt in $2.2B deal for food allergy drug | ||
| 20.01. | Kailera's Ron Renaud on how a China-linked startup can compete in obesity | ||
| 20.01. | When every day counts: Building CRO partnerships on a foundation of trust, care and precision | ||
| 20.01. | The patient retention crisis is happening before enrollment even begins | ||
| 16.01. | Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.